Mutual Funds Sahi Hai!
To avail the service, you will be redirected to loans.geojitcredits.com
Divis Laboratories Ltd is down for a fifth straight session today. The stock is quoting at Rs 5722.5, down 2.96% on the day as on 13:19 IST on the NSE. The benchmark NIFTY is down around 0.54% on the day, quoting at 24755.4. The Sensex is at 80723.46, down 0.54%.Divis Laboratories Ltd has lost around 6.68% in last one month.Meanwhile, Nifty Pharma index of which Divis Laboratories Ltd is a constituent, has eased around 1.23% in last one month and is currently quoting at 21977.7, down 1.99% on the day. The volume in the stock stood at 4.33 lakh shares today, compared to the daily average of 3.53 lakh shares in last one month.
The benchmark September futures contract for the stock is quoting at Rs 5701.5, down 3.58% on the day. Divis Laboratories Ltd jumped 4.85% in last one year as compared to a 5.44% slide in NIFTY and a 8.41% fall in the Nifty Pharma index.
The PE of the stock is 67.03 based on TTM earnings ending June 25.
Divis Laboratories Ltd gained for a third straight session today. The stock is quoting at Rs 6247.5, up 1.56% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is up around 0.49% on the day, quoting at 24991.1. The Sensex is at 81715.66, up 0.5%. Divis Laboratories Ltd has slipped around 5.11% in last one month.
Meanwhile, Nifty Pharma index of which Divis Laboratories Ltd is a constituent, has slipped around 1.85% in last one month and is currently quoting at 22265, up 0.34% on the day. The volume in the stock stood at 2.83 lakh shares today, compared to the daily average of 4.49 lakh shares in last one month.
The benchmark August futures contract for the stock is quoting at Rs 6240, up 1.54% on the day. Divis Laboratories Ltd is up 26.82% in last one year as compared to a 0.08% drop in NIFTY and a 0.95% drop in the Nifty Pharma index.
The PE of the stock is 69.89 based on TTM earnings ending June 25.
Over the past month, the stock has fallen 7.08% compared with a 0.84% decline in the Sensex.
Divis Laboratories is engaged in the manufacture of active pharmaceutical ingredients, intermediates and nutraceutical ingredients. The company's consolidated net profit rose 26.74% to Rs 545 crore while net sales rose 13.79% to Rs 2410 crore in Q1 June 2025 over Q1 June 2024.